Molecular Dx Coalition Seeks to Prod CMS to Restore Test Pricing During Review | GenomeWeb

NEW YORK (GenomeWeb News) – Clinical lab organizations and a number of companies that develop and make molecular diagnostics have banded together to create a group to press for better government reimbursement while the US Centers for Medicare and Medicaid Services works to restructure its pricing plans.

The Coalition to Strengthen the Future of Molecular Diagnostics said last week that it has launched because CMS has been paying lower reimbursement rates while it conducts a review of its process for pricing these tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.